HIV-1 entry inhibitors: closing the front door

Bibliography

• BERGER EA, MURPHY PM, FARBER JM: Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Anna. Rev Intinunol. (1999) 17:657–700.
   PubMed Web of Science ®Google Scholar
• ••Excellent overview of chemokine receptorutilisation for entry and their role in pathogenesis.
   Google Scholar
• ECKERT DM, KIM PS: Mechanisms of viral membrane fusion and its inhibition. Anna. Rev Biochein. (2001) 70:777–810.
   PubMed Web of Science ®Google Scholar
• ••Excellent review of entry and fusion,with special emphasis on parallels between HIV and influenza entry mechanisms.
   Google Scholar
• ZIMMERBERG J, CHERNOMORDIK LV: Membrane fusion. Adv. Drug Deify. Rev. (1999) 38:197–205.
   PubMed Web of Science ®Google Scholar
• DOMS RW, MOORE JP: HIV-1 membrane fusion: targets of opportunity. Cell Biol. (2000) 151:F9–14.
   PubMed Web of Science ®Google Scholar
• LEE C, LIU QH, TOMKOWICZ B et al:Macrophage activation through CCR5- and CXCR4-mediated gp120-elicited signaling pathways.' Leukoc. Biol. (2003) 74:676–682.
   PubMed Web of Science ®Google Scholar
• MARINISSEN MJ, GUTKIND JS: G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Phannacol Sri. (2001) 22:368–376.
   PubMed Web of Science ®Google Scholar
• FENG Y, BRODER CC, KENNEDY PE, BERGER EA: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (1996) 272:872–877.
   PubMed Web of Science ®Google Scholar
• ••The discovery of a co-receptor that serves inconjunction with CD4 for HIV-1 entry, a 7T1VI GPCR later identified as the chemokine receptor CXCR4.
   Google Scholar
• DORANZ BJ, RUCKER J, YI Y et al: A dual-tropic primary HIV-1 isolate that uses fusin and the I3-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell (1996) 85:1149–1158.
   PubMed Web of Science ®Google Scholar
• DENG H, LIU R, ELLMEIER W et al.: Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 381:661–666.
   PubMed Web of Science ®Google Scholar
• •The latter two papers demonstrated that CCR5 is the entry co-receptor used by the largest group of primary HIV-1 isolates.
   Google Scholar
• VAN'T WOUT AB, KOOTSTRA NA, MULDER-KAMPINGA GA et al.: Macrophage-tropic variants initiate human immunodeficiency virus Type 1 infection after sexual, parenteral, and vertical transmission. Clin. Invest. (1994) 94:2060–2067.
   Google Scholar
• ZHU T, MO H, WANG N et al: Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science (1993) 261:1179–1181.
   PubMed Web of Science ®Google Scholar
• •Evidence that macrophage-tropic non-syncytia-inducing variants, later identified as CCR5-using (R5) strains, are responsible for transmission and the establishment of infection.
   Google Scholar
• CONNOR RI, SHERIDAN KE, CERADINI D, CHOE S, LANDAU NR: Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. I Exp. Med. (1997) 185:621–628.
   PubMed Web of Science ®Google Scholar
• •Clear evidence that viral phenotypic evolution, known to occur in vivo in association with accelerated disease progression, is due to a change in chemokine receptor utilisation.
   Google Scholar
• SCHUITEMAKER H, KOOTSTRA NA, DE GOEDE RE et al.: Monocytotropic human immunodeficiency virus Type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture.' Virol. (1991) 65:356–363.
   Google Scholar
• •One in a series of important studies from this group demonstrating that viral phenotype evolves in vivo, later discovered to be due to a shift in chemokine receptor preference.
   Google Scholar
• COLLMAN RG, YI Y, LIU QH, FREEDMAN BD: Chemokine signaling and HIV-1 fusion mediated by macrophage CXCR4: implications for target cell tropism. Leukoc. Biol. (2000) 68:318–323.
   PubMedGoogle Scholar
• LIU R, PAXTON WA, CHOE S et al.: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell (1996) 86:367–377.
   PubMed Web of Science ®Google Scholar
• SAMSON M, LIBERT F, DORANZ BJ et al.: Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996) 382:722–725.
   PubMed Web of Science ®Google Scholar
• ••The latter two papers demonstrated that CCR5 is critical for person-to-person transmission of HIV-1, based on natural resistance to infection among individuals who lack functional CCR5 expression.
   Google Scholar
• BENKIRANE M, JIN DY, CHUN RF, KOUP RA, JEANG KT: Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5432. J. Biol. Chem. (1997) 272:30603–30606.
   PubMed Web of Science ®Google Scholar
• DEAN M, CARRINGTON M, WINKLER C et al.: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science (1996) 273:1856–1862.
   Google Scholar
• ••Evidence that infected individualsheterozygous for a defective CCR5 allele have slower disease progression.
   Google Scholar
• BASHIROVA AA, GEIJTENBEEK TB, VAN DUIJNHOVEN GC et al.: A dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN)-related protein is highly expressed on human liver sinusoidal endothelial cells and promotes HIV-1 infection. I Exp. Med. (2001) 193:671–678.
   Google Scholar
• GEIJTENBEEK TB, KWON DS, TORENSMA R et al.: DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell (2000) 100:587–597.
   PubMed Web of Science ®Google Scholar
• GEIJTENBEEK TB, TORENSMA R, VAN VLIET SJ et al.: Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell (2000) 100:575–585.
   Google Scholar
• CAMERON PU, FREUDENTHAL PS, BARKER JM et al.: Dendritic cells exposed to human immunodeficiency virus Type-1 transmit a vigorous cytopathic infection to CD4' T cells. Science (1992) 257:383–387.
   PubMed Web of Science ®Google Scholar
• FEINBERG H, MITCHELL DA, DRICKAMER K, WEIS WI: Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR. Science (2001) 294:2163–2166.
   PubMed Web of Science ®Google Scholar
• KAZMIERSKI W, BIFULCO N, YANG H et al.: Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors. Bioorg. Med. Chem. (2003) 11:2663–2676.
   PubMed Web of Science ®Google Scholar
• MOORE JP, DOMS RW: The entry of entry inhibitors: a fusion of science and medicine. Proc. Natl. Acad. Sci. USA (2003) 100:10598–10602.
   PubMed Web of Science ®Google Scholar
• •Excellent review that focuses particularly on how the dynamics of entry and fusion may affect the efficiency of inhibitors.
   Google Scholar
• KILBYJM, ERON JJ: Novel therapies basedon mechanisms of HIV-1 cell entry. N Engl. I Med. (2003) 348:2228–2238.
   PubMedGoogle Scholar
• STARR-SPIRES LD, COLLMAN RG: HIV-1 entry and entry inhibitors as therapeutic agents. Clin. Lab. Med. (2002) 22:681–701.
   PubMedGoogle Scholar
• NOVINA CD, MURRAY ME DYKXHOORN DM et al.: siRNA-directed inhibition of HIV-1 infection. Nat. Med. (2002) 8:681–686.
   Google Scholar
• CHEN JD, BAI X, YANG AG, CONG Y,CHEN SY: Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy. Nat. Med. (1997) 3:1110–1116.
   PubMed Web of Science ®Google Scholar
• SMITH DH, BYRN RA, MARSTERS SA et al.: Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science (1987) 238: 1704-1707.
   Google Scholar
• •The first attempt at entry blocking, which worked in vitro but, ultimately, not in vivo.
   Google Scholar
• SCHOOLEY RT, MERIGAN TC, GAUT P et al.: Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A Phase I - II escalating dosage trial. Ann. Intern. Med. (1990) 112:247–253.
   PubMed Web of Science ®Google Scholar
• SCHACKER T, COLLIER AC, COOMBS R et al.: Phase I study of high-dose, intravenous rsCD4 in subjects with advanced HIV-1 infection. Acquir. Immune Defic. Syndr. (1995) 9:145–152.
   Google Scholar
• DAAR ES, LI XL, MOUDGIL T, HO DD:High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus Type 1 isolates. Proc. Nati Acad. Sri. USA (1990) 87:6574–6578.
   PubMed Web of Science ®Google Scholar
• MOORE JP, MCKEATING JA, HUANG YX, ASHKENAZI A, HO DD: Virions of primary human immunodeficiency virus Type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. I Virol. (1992) 66:235–243.
   PubMedGoogle Scholar
• •The latter four papers identified and addressed the discrepancy between effective entry blocking by rsCD4 in vitro and the lack of efficacy in vivo.
   Google Scholar
• TRKOLA A, POMALES AB, YUAN H et al.: Cross-clade neutralization of primary isolates of human immunodeficiency virus Type 1 by human monoclonal antibodies and tetrameric CD4-IgG. Vim/. (1995) 69:6609–6617.
   Google Scholar
• •Entry inhibition using a multivalent rsCD4-antibody fusion protein, which is now in clinical studies.
   Google Scholar
• GAUDUIN MC, ALLAWAY GP, OLSON WC et al.: CD4-immunoglobulin G2 protects Hu-PBL-SCID mice against challenge by primary human immunodeficiency virus Type 1 isolates.Virol. (1998)72:3475–3478.
   Google Scholar
• JACOBSON JM, LOWY I, FLETCHER CV et al.: Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) Type 1 entry inhibitor PRO 542 in HIV-infected adults. Infect. Dis. (2000) 182:326–329.
   Web of Science ®Google Scholar
• SHEARER WT, ISRAEL RJ, STARR S et al.: Recombinant CD4-IgG2 in human immunodeficiency virus Type 1-infected children: Phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team. Infect. Dis. (2000) 182:1774–1779.
   Google Scholar
• WANG T, ZHANG Z, WALLACE OB et al.: Discovery of 4-benzoy1-1- [(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacety11-2-(R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. Med. Chem. (2003) 46:4236–4239.
   Web of Science ®Google Scholar
• GUO Q, HO HT, DICKER I et al.: Biochemical and genetic characterizations of a novel human immunodeficiency virus Type 1 inhibitor that blocks gp120-CD4 interactions.Virol. (2003) 77:10528–10536.
   Web of Science ®Google Scholar
• LIN PF, BLAIR W, WANG T et al.: A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Nati Acad. Sci. USA (2003) 100:11013–11018.
   PubMed Web of Science ®Google Scholar
• •A unique small-molecule inhibitor that targets the conserved CD4-binding site on gp120 and blocks CD4 interactions.
   Google Scholar
• HANNA G, YAN JH, FISKE W et al.: Safety, tolerability, and pharmacokinetics of a novel, small-molecule HIV-1 attachment inhibitor, BMS-488043, after single and multiple oral doses in healthy subjects. In: Abstracts of the I I th Conference on Retro viruses and Opportunistic Infections. San Francisco, CA, USA. February 8-11 (2004):535.
   Google Scholar
• HANNA G, LALEZARI J, HELLINGER J et al.: Antiviral activity, safety, and tolerability of a novel, oral small-molecule HIV-1 attachment inhibitor, BMS-488043, in HIV1-infected subjects. In: Abstracts of the I I th Conference on Retro viruses and Opportunistic Infections. San Francisco, CA, USA. February 8-11 (2004):141.
   Google Scholar
• LIN PF, HO HT, GONG YF et al.: Characterization of a small molecule HIV-1 attachment inhibitor BMS-488043: virology, resistance and mechanism of action. In: Abstracts of the I I th Conference on Retro viruses and Opportunistic Infections. San Francisco, CA, USA. February 8-11 (2004):534.
   Google Scholar
• VERMEIRE K, BELL TW, CHOI HJ et al.: The anti-HIV potency of cyclotriazadisulfonamide analogs is directly correlated with their ability to down-modulate the CD4 receptor. Mol. Pbarmacol. (2003) 63:203–210.
   PubMed Web of Science ®Google Scholar
• VERMEIRE K, ZHANG Y, PRINCEN K et al.: CADA inhibits human immunodeficiency virus and human herpesvirus 7 replication by down-modulation of the cellular CD4 receptor. Virnlogy(2002) 302:342–353.
   PubMed Web of Science ®Google Scholar
• CRUIKSHANK WW, KORNFELD H, CENTER DM: Interleuldn-16. Leukoc. Biol. (2000) 67:757–766.
   PubMed Web of Science ®Google Scholar
• MITSUYA H, LOONEY DJ, KUNO S et al.: Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4' cells. Science (1988) 240:646–649.
   PubMed Web of Science ®Google Scholar
• SCHOLS D, BABA M, PAUWELS R, DESMYTER J, DE CLERCQ E: Specific interaction of aurintricarboxylic acid with the human immunodeficiency virus/ CD4 cell receptor. Proc. Natl. Acad. Sci. USA (1989) 86:3322–3326.
   PubMed Web of Science ®Google Scholar
• YAO XJ, WAINBERG MA, POLLAK M: The inhibitory effects of suramin on HIV-1 are attenuated in the presence of albumin. AIDS(1991) 5:1389–1391.
   PubMedGoogle Scholar
• WYATT R, KWONG PD, DESJARDINS E et al.: The antigenic structure of the HIV gp120 envelope glycoprotein. Nature (1998) 393:705–711.
   PubMed Web of Science ®Google Scholar
• RICHMAN DD, WRIN T, LITTLE SJ, PETROPOULOS CJ: Rapid evolution of the neutralizing antibody response to HIV Type 1 infection. Proc. Natl. Acad. St". USA (2003) 100:4144–4149.
   PubMed Web of Science ®Google Scholar
• WEI X, DECKER JM, WANG S et al.: Antibody neutralization and escape by HIV-1. Nature (2003) 422:307–312.
   PubMed Web of Science ®Google Scholar
• LABRIJN AF, POIGNARD P, RAJA A et al.: Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus Type 1.Virol. (2003) 77:10557–10565.
   Google Scholar
• REITTER JN, MEANS RE, DESROSIERS RC: A role for carbohydrates in immune evasion in AIDS. Nat. Med. (1998) 4:679–684.
   PubMed Web of Science ®Google Scholar
• KOCH M, PANCERA M, KWONG PD et al.: Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology (2003) 313:387–400.
   PubMedGoogle Scholar
• ZOLLA-PAZNER S: Identifying epitopes ofHIV-1 that induce protective immunity. Nat. Rev Immunol. (2004) 4:199–210.
   PubMed Web of Science ®Google Scholar
• BURTON DR, DESROSIERS RC, DOMS RW et al.: HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. (2004) 5:233–236.
   PubMed Web of Science ®Google Scholar
• •The above two papers proved an excellent review of the challenges involved in developing antibodies that neutralise HIV-1 and/or block gp120 interactions with the entry receptor complex.
   Google Scholar
• HUANG Y, PAXTON WA, WOLINSKY SM et al.: The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat. Med. (1996) 2:1240–1243.
   PubMed Web of Science ®Google Scholar
• COCCHI F, DEVICO AL, GARZINO-DEMO A et al.: Identification of RANTES, MIP-la, and MIP-113 as the major HIV-suppressive factors produced by CD8' T cells. Science (1995) 270: 1811-1815.
   Google Scholar
• ••First evidence that viral entry can beblocked by agents that target CCR5, in this case by the natural chemokine ligands.
   Google Scholar
• MACK M, LUCKOW B, NELSON PJ et al.: Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. I Exp. Med. (1998) 187:1215–1224.
   PubMed Web of Science ®Google Scholar
• PASTORE C, PICCHIO GR, GALIMI F et al.: Two mechanisms for human immunodeficiency virus Type 1 inhibition by N-terminal modifications of RANTES. Antimicrob. Agents Chemother: (2003) 47:509–517.
   Google Scholar
• SIMMONS G, REEVES JD, HIBBITTS S et al.: Co-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands. Immunol Rev (2000) 177:112–126.
   PubMed Web of Science ®Google Scholar
• BABA M, NISHIMURA O, KANZAKI N et al.: A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. NatL Acad. Sci. USA (1999) 96:5698–5703.
   PubMed Web of Science ®Google Scholar
• •The first small molecule that blocked CCR5-mediated entry.
   Google Scholar
• DRAGIC T, TRKOLA A, THOMPSON DA et at A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl. Acad. Sci USA (2000) 97:5639–5644.
   PubMed Web of Science ®Google Scholar
• LIZAWA Y, KANZAKI N, TAKASHIMA K: Anti-viral activity of TAK-220, a small molecule CCR5 antagonist. In: Abstracts of the 10th Conference on Retro viruses and Opportunistic Infections. Boston, MA, USA. February 10-14 (2003):11.
   Google Scholar
• TREMBLAY CL, GIGUEL F, HICKS JL et al.: TAK-220, a novel small molecule inhibitor of CCR5 has favorable anti-HIV interactions with other anti-retrovirals in vitro. In: Abstracts of the 10th Conference on Remo viruses and Opportunistic Infections. Boston, MA, USA. February 10-14 (2003):562.
   Google Scholar
• STRIZKI JM, XU S, WAGNER NE et al: SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection M vitro and in vivo. Proc. Natl. Acad. ScL USA (2001) 98:12718–12723.
   PubMed Web of Science ®Google Scholar
• TAGAT JR, MCCOMBIE SW, STEENSMA RW et al.: Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-methyl piperazine as a key pharmacophore element. Bioorg. Med. Chem. Lett. (2001) 11:2143–2146.
   Google Scholar
• TSAMIS F, GAVRILOV S, KAJUMO F et al.: Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus Type 1 entry.' Virol (2003) 77:5201–5208.
   PubMed Web of Science ®Google Scholar
• REYNES J, ROUZIER R, KANOUNI T et al: SCH C: safety and antiviral effects of a CCR5 receptor antagonist in HIV-1-infected subjects. In: Abstracts of the 9th Conference on Remo viruses and Opportunistic Infections. Seattle, WA, USA. February 24-28 (2002):1.
   Google Scholar
• •The first evidence that CCR5 blocking suppresses HIV-1 in infected individuals.
   Google Scholar
• CHEN Z, HUB, HUANG W et al.: HIV-1 mutants less susceptible to SCH-D, a novel small-molecule antagonist of CCR5. In: Abstracts of the 9th Conference on Remo viruses and Opportunistic Infections. Seattle, WA, USA. February 24-28 (2002):396–T.
   Google Scholar
• SCHURMANN D, ROUZIER R, NOUGAREDE R et al: SCH D: antiviral activity of a CCR5 receptor antagonist. In: Abstracts of the 11th Conference on Remo viruses and Opportunistic Infections. San Francisco, CA, USA. February 8–11 (2004) :140LB.
   Google Scholar
• DORR P, MACARTNEY M, RICKETT G et al: UK-427,857, a novel small molecule hiv entry inhibitor is a specific antagonist of the chemokine receptor CCR5. In: Abstracts of the 10th Conference on Remo viruses and Opportunistic Infections. Boston, MA, USA. February 10-14 (2003):12.
   Google Scholar
• MACARTNEY MJ et al.: In vitro antiviral profile of entry inhibitor UK-427,857. In: Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL, USA. September 14-17 (2003):H–875.
   Google Scholar
• NAPIER C, DORR P, GLADUE R et al.: The preclinical pharmacokinetics and safety pharmacology of the anti-HIV CCR antagonist, UK-427,857. In: Abstracts of the 10th Conference on Retro viruses and Opportunistic Infections. Boston, MA, USA. February 10-14 (2003):546–A.
   Google Scholar
• POZNIAK AL et al.: Effect of short-term monotherapy with UK-427,857 on viral load in HIV-infected patients. In: Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL, USA. September 14-17 (2003):H–443.
   Google Scholar
• MAEDA K, YOSHIMURA K, SHIBAYAMA S et al.: Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. J. Biol. Chem. (2001) 276:35194–35200.
   PubMed Web of Science ®Google Scholar
• MAEDA K, NAKATA H, MIYAKAWA T et al.: CCR5 binding profiles of AF602/ ONO-4128, a novel HIV-specific and potent anti-HIV spiroketopiperazine (SDP) derivative, differ from those other existing CCR5 inhibitors. In: Abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France. July 13-16 (2003):531. ao.LYNCH CL, HALE JJ, BUDHU RJ et aL: CCR5 antagonists: 3-(pyrrolidin-1-Apropionic acid analogues with potent anti-HIV activity. Org. Lett. (2003) 5:2473–2475.
   Google Scholar
• VEAZEY RS, KLASSE PJ, KETAS TJ et al: Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. Exp. Med. (2003) 198:1551–1562.
   PubMed Web of Science ®Google Scholar
• FRANTI M, NAGASHIMA KA, MADDON PJ et al: The CCR5 co-receptor inhibitor PRO 140 effectively controls established HIV-1 infection in vivo. In: Abstracts of the 9th Conference on Redoviruses and Opportunistic Infections. Seattle, WA, USA. February 24-28 (2002):403–T.
   Google Scholar
• OLSON WC, GARDNER JP, KETAS TJ: Inhibition of HIV-1 entry without coreceptor antagonism by the humanized anti-CCR5 antibody PRO 140. In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, CA, USA. September 27-31 (2002):H–178.
   Google Scholar
• TRKOLA A, KETAS TJ, NAGASHIMA KA et al.: Potent, broad-spectrum inhibition of human immunodeficiency virus Type 1 by the CCR5 monoclonal antibody PRO 140. Virol (2001) 75:579–588.
   Web of Science ®Google Scholar
• CORMIER EG, KETAS TJ, SULLIVAN BM: Baseline viral susceptibility to the CCR5 co-receptor inhibitor PRO140. In: Abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France. July 13-16 (2003):530.
   Google Scholar
• ZOU YR, KOTTMANN AH, KURODA M, TANIUCHI I, LITTMAN DR: Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature (1998) 393:595–599.
   PubMed Web of Science ®Google Scholar
• TACHIBANA K, HIROTA S, IIZASA H et al.: The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature (1998) 393:591–594.
   PubMed Web of Science ®Google Scholar
• CAMPBELL DJ, KIM CH, BUTCHER EC: Chemokines in the systemic organization of immunity. Immunol. Rev (2003) 195:58–71.
   PubMed Web of Science ®Google Scholar
• SCHOLS D, STRUYF S, VAN DAMME J et al.: Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. I Exp. Med. (1997) 186:1383–1388.
   Google Scholar
• •The first small-molecule CXCR4 inhibitor.
   Google Scholar
• DE CLERCQ E: The bicyclam AMD3100 story. Nat. Rev Drug Discov. (2003) 2:581–587.
   PubMed Web of Science ®Google Scholar
• DONZELLA GA, SCHOLS D, LIN SW et al: AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med. (1998) 4:72–77.
   PubMed Web of Science ®Google Scholar
• DATEMA R, RABIN L, HINCENBERGS M et al: Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 GM 3100), an inhibitor of infectious cell entry. Antimicrob. Agents Chemother. (1996) 40:750–754.
   PubMed Web of Science ®Google Scholar
• HENDRIX CW, FLEXNER C, MACFARLAND RT et al.: Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob. Agents Chemother. (2000) 44:1667–1673.
   PubMed Web of Science ®Google Scholar
• SCHOLS D, CLAES S, DE CLERCQ E et al.: AMD-3100, a CXCR4 antagonist, reduced HIV viral load and X4 viral levels in humans. In: Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, USA. February 24-28 (2002):2.
   Google Scholar
• •Evidence for some limited efficacy of CXCR4 blocking in vivo, which highlights the importance of viral phenotyping in selecting co-receptor antagonists.
   Google Scholar
• LILES WC, BROXMEYER HE, ROD GER E et al.: Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood (2003) 102:2728–2730.
   Google Scholar
• ••Evidence that CXCR4 blocking has majoreffects on the haematopoietic system, which highlights potential new uses for blocking agents, and offers a caution regarding chronic use in infected individuals.
   Google Scholar
• SCHOLS D, CLAES S, HATSE S et al.: Anti-HIV activity profile of AMD070, an orally bioavailable CXCR4 antagonist. In: Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA. February 10-14 (2003):563.
   Google Scholar
• ICHIYAMA K, YOKOYAMA-KUMAKURA S, TANAKA Y et al.: A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. USA (2003) 100:4185–4190.
   PubMed Web of Science ®Google Scholar
• MURAKAMI T, NAKAJIMA T, KOYANAGI Y et al.: A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. Exp. Med. (1997) 186:1389–1393.
   PubMed Web of Science ®Google Scholar
• MURAKAMI T, ZHANG TY, KOYANAGI Y et al: Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus Type 1 infection.Virol. (1999) 73:7489–7496.
   Web of Science ®Google Scholar
• TAMAMURA H, HIRAMATSU K, MIZUMOTO Metal.: Enhancement of the T140-based pharmacophores leads to the development of more potent and bio-stable CXCR4 antagonists. Org. Biomol. Chem. (2003) 1:3663–3669.
   Google Scholar
• TAMAMURA H, HIRAMATSU K, KUSANO S et al.: Synthesis of potent CXCR4 inhibitors possessing low cytotoxicity and improved biostability based on T140 derivatives. Org. Biomol. Chem. (2003) 1:3656–3662.
   PubMed Web of Science ®Google Scholar
• ARAKAKI R, TAMAMURA H, PREMANATHAN M et al.: T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure.Virol. (1999)73:1719–1723.
   Google Scholar
• DORANZ BJ, GROVIT-FERBAS K, SHARRON MP et al.: A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. Exp. Med. (1997) 186:1395–1400.
   PubMed Web of Science ®Google Scholar
• LUO Z, ZHOU N, LUO J, HALL JVV, HUANG Z: The role of positively charged residues in CXCR4 recognition probed with synthetic peptides. Biochem. Biophys. Res. Commun. (1999) 263:691–695.
   PubMed Web of Science ®Google Scholar
• DORANZ BJ, FILION LG, DIAZ-MITOMA F et al: Safe use of the CXCR4 inhibitor ALX40-4C in humans. AIDS Res. Hum. Removiruses (2001) 17:475–486.
   PubMed Web of Science ®Google Scholar
• YANG OO, SWANBERG SL, LU Z et al: Enhanced inhibition of human immunodeficiency virus Type 1 by Met-stromal-derived factor 113 correlates with down-modulation of CXCR4. .1 Virol. (1999) 73:4582–4589.
   PubMed Web of Science ®Google Scholar
• CHEN CH, MATTHEWS TJ, MCDANAL CB, BOLOGNESI DP, GREENBERG ML: A molecular clasp in the human immunodeficiency virus (HIV) Type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. .1 Virol. (1995) 69:3771–3777.
   PubMed Web of Science ®Google Scholar
• KILBY JM, HOPKINS S, VENETTA TM et al.: Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. (1998) 4:1302–1307.
   PubMed Web of Science ®Google Scholar
• ••First demonstration that entry inhibition,by a peptide that blocks gp41 structural reorganisation required for fusion, has antiretroviral efficacy in vivo.
   Google Scholar
• LAZZARIN A, CLOTET B, COOPER D et al.: Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl. I Med. (2003) 348:2186–2195.
   PubMed Web of Science ®Google Scholar
• LALEZARI JP, HENRY K, O'HEARN M et al: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl. I Med. (2003) 348:2175–2185.
   PubMed Web of Science ®Google Scholar
• •The above two papers demonstrate in two large Phase III studies of individuals with drug-resistant viruses, that the fusion inhibitor T-20 improves viral control when added to an otherwise optimal HAART regimen.
   Google Scholar
• ERON JJ, MERIGAN TC, KILBY M et al.: A 14-day assessment of the safety, pharmacokinetics, and antiviral activity of T-1249, a peptide inhibitor of membrane fusion. In: Abstracts of the 8th Conference on Remo viruses and Opportunistic Infections. Chicago, IL, USA. February 4-8 (2001):14.
   Google Scholar
• REEVES JD, GALLO SA, AHMAD N et al.: Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc. Natl. Acad. Sci. USA (2002) 99:16249–16254.
   PubMed Web of Science ®Google Scholar
• •An excellent discussion of the complex factors that determine sensitivity to entry inhibitor agents.
   Google Scholar
• DERDEYN CA, DECKER JM, SFAKIANOS JN et al: Sensitivity of human immunodeficiency virus Type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. Virol. (2000) 74:8358–8367.
   Google Scholar
• ROOT MJ, KAY MS, KIM PS: Protein design of an HIV-1 entry inhibitor. Science (2001) 291:884–888.
   PubMed Web of Science ®Google Scholar
• TREMBLAY CL, GIGUEL F, KOLLMANN C et al: Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents M vitro. Antimicrob. Agents Chemother. (2002) 46:1336–1339.
   PubMed Web of Science ®Google Scholar
• SINGH A, COLLMAN RG: Heterogeneous spectrum of coreceptor usage among variants within a dualtropic human immunodeficiency virus Type 1 primary-isolate quasispecies. Vim/. (2000) 74:10229–10235.
   Google Scholar
• TRKOLA A, KUHMANN SE, STRIZKI JM et al.: HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc. Natl. Acad. Sci. USA (2002) 99:395–400.
   PubMed Web of Science ®Google Scholar
• MOSIER DE, PICCHIO GR, GULIZIA RJ et al.: Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus Type 1 infection in vivo or rapidly select for CXCR4-using variants.' VIM]. (1999) 73:3544–3550.
   Google Scholar
• ••The above two studies come to oppositeconclusions regarding the important question of whether or not CCR5 blockade leads to the emergence of CXCR4-using variants, which might potentially have deleterious consequences in vivo.
   Google Scholar
• LANGENKAMP A, NAGATA K, MURPHY K et al: Kinetics and expression patterns of chemokine receptors in human CD4' T lymphocytes primed by myeloid or plasmacytoid dendritic cells. Ear' Immunol. (2003) 33:474–482.
   PubMedGoogle Scholar
• LEES, TIFFANY HL, KING L et al: CCR8 on human thymocytes functions as a human immunodeficiency virus Type 1 coreceptor." Virol. (2000) 74:6946–6952.
   PubMed Web of Science ®Google Scholar
• CHEN Z, KWON D, JIN Z et al: Natural infection of a homozygous 824 CCR5 red-capped mangabey with an R2b-tropic simian immunodeficiency virus. J. Exp. Med. (1998) 188:2057–2065.
   PubMedGoogle Scholar
• ZHANG YJ, MOORE JP: Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus Type 1 entry? Virol. (1999) 73:3443–3448.
   Google Scholar
• RESCH W, HOFFMAN N, SWANSTROM R: Improved success of phenotype prediction of the human immunodeficiency virus Type 1 from envelope variable loop 3 sequence using neural networks. Virology (2001) 288:51–62.
   PubMed Web of Science ®Google Scholar
• LABROSSE B, LABERNARDIERE JL, DAM E et al.: Baseline susceptibility of primary human immunodeficiency virus Type 1 to entry inhibitors. Virol. (2003) 77:1610–1613.
   Google Scholar
• •Evidence that HIV-1 variants have a greater range of baseline sensitivity to entry inhibitors than they have to drugs that target other steps in the viral life cycle.
   Google Scholar
• TANG J, RIVERS C, KARITA E et al.: Allelic variants of human I3-chemokine receptor 5 (CCR5) promoter: evolutionary relationships and predictable associations with HIV-1 disease progression. Genes Immun. (1999) 1:20–27.
   PubMedGoogle Scholar
• BELNOUE E, KAYIBANDA M, DESCHEMIN JC et al.: CCR5 deficiency decreases susceptibility to experimental cerebral malaria. Blood (2003) 101:4253–4259.
   PubMed Web of Science ®Google Scholar
• GLASS WG, LANE TE: Functional analysis of the CC chemokine receptor 5 (CCR5) on virus-specific CD8' T cells following coronavirus infection of the central nervous system. Virology (2003) 312:407–414.
   PubMed Web of Science ®Google Scholar
• GLASS WG, LANE TE: Functional expression of chemokine receptor CCR5 on CD4(*) T cells during virus-induced central nervous system disease. Virol. (2003) 77:191–198.
   Google Scholar
• LUANGSAY S, KASPER LH, RACHINEL N et al.: CCR5 mediates specific migration of Toxoplasma gondli-primed CD8 lymphocytes to inflammatory intestinal epithelial cells. Gastroenterology (2003) 125:491–500.
   PubMedGoogle Scholar
• HONCZARENKO M, LE Y, GLODEK AM et al: CCR5-binding chemokines modulate CXCL12 (SDF-1) -induced responses of progenitor B cells in human bone marrow through heterologous desensitization of the CXCR4 chemokine receptor. Blood (2002) 100:2321–2329.
   PubMedGoogle Scholar
• LAPIDOT T, KOLLET O: The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/ SCID/B2m(null) mice. Leukemia (2002) 16: 1992-2003.
   Google Scholar
• ZHANG WB, NAVENOT JM, HARIBABU B et al.: A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. Biol. Chem. (2002) 277:24515–24521.
   Web of Science ®Google Scholar
• ESSER MT, MORI T, MONDOR I et al.: Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus Type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120. Virol. (1999) 73:4360–4371.
   Web of Science ®Google Scholar
• TSAI CC, EMAU P, JIANG Yet al.: Cyanovirin-N gel as a topical microbicide prevents rectal transmission of 5HIV89.6P in macaques. AIDS Res. Hum. Retro viruses (2003) 19:535–541.
   Google Scholar
• CHANG TL, CHANG CH, SIMPSON DA et al.: Inhibition of HIV infectivity by a natural human isolate of Lactobacillusjensenii engineered to express functional two-domain CD4. Proc. Nati Acad. Sri. USA (2003) 100:11672–11677.
   PubMed Web of Science ®Google Scholar
• YANG YE MUKAI T, GAO P et al.: A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses. Ear: Immunol. (2002) 32:2124–2132.
   Google Scholar
• RUBIN JB, KUNG AL, KLEIN RS et al: A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc. Natl. Acad. Sci. USA (2003) 100:13513–13518.
   PubMed Web of Science ®Google Scholar
• TAMAMURA H, HORI A, KANZAKI N et al.: T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett. (2003) 550:79–83.
   PubMed Web of Science ®Google Scholar